Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Braftovi“
Suchtreffer
Begriffe & Kennungen
Braftovi · 4.8 · In Study CMEK162B2301-Part 2, in the Combo 300 arm, RPED was observed in 12.5% (32/257) of patients with 0.4%
Eintrag öffnenBraftovi · 4.8 · In Study CMEK162B2301-Part 2, in the Combo 300 arm, anaemia was observed in 9.7% (25/257) of patients with Gra
Eintrag öffnenBraftovi · 4.8 · In Study CMEK162B2301-Part 2, in the Combo 300 arm, fatigue was observed in 33.5% (86/257) of patients with 1.
Eintrag öffnenBraftovi · 4.8 · In Study CMEK162B2301-Part 2, in the Combo 300 arm, haemorrhagic events were observed in 6.6% (17/257) of pati
Eintrag öffnenBraftovi · 4.8 · In Study CMEK162B2301-Part 2, in the Combo 300 arm, headache was reported in 12.1% (31/257) of patients and wa
Eintrag öffnenBraftovi · 4.8 · In Study CMEK162B2301-Part 2, in the Combo 300 arm, the incidence of liver laboratory abnormalities was: • Inc
Eintrag öffnenBraftovi · 4.8 · In the Combo 300 arm in Part 2 of the pivotal study, PPES was observed in 3.9% (10/257) of patients with Grade
Eintrag öffnenBraftovi · 4.8 · In the colorectal cancer population, due to a very small number of patients treated in the age subgroup of pat
Eintrag öffnenBraftovi · 4.8 · In the pooled encorafenib 300 population, PPES was reported in 51.6% (112/217) of patients. Most events were m
Eintrag öffnenBraftovi · 4.8 · In the pooled encorafenib 300 population, cuSCC was reported in 7.4% (16/217) patients. For patients in the Ph
Eintrag öffnenBraftovi · 4.8 · In the pooled encorafenib 300 population, facial paresis was observed in 7.4% (16/217) of patients. Most event
Eintrag öffnenBraftovi · 4.8 · In the pooled encorafenib 300 population, photosensitivity was reported in 4.1% (9/217) of patients. All event
Eintrag öffnenBraftovi · 4.8 · In the pooled encorafenib 300 population, rash was reported in 43.3% (94/217) of patients. Most events were mi
Eintrag öffnenBraftovi · 4.8 · Left ventricular dysfunction LVD was reported when encorafenib is used in combination with binimetinib in mela
Eintrag öffnenBraftovi · 4.8 · Liver laboratory abnormality Melanoma and NSCLC The incidences of liver laboratory abnormalities reported in t
Eintrag öffnenBraftovi · 4.8 · New primary melanoma Melanoma In the pooled encorafenib 300 population, new primary melanoma events occurred i
Eintrag öffnenBraftovi · 4.8 · Palmar-plantar erythrodysaesthesia syndrome (PPES) Melanoma and NSCLC PPES was reported in 5.1% (19/372) of pa
Eintrag öffnenBraftovi · 4.8 · Photosensitivity Melanoma and NSCLC In the Combo 450 ISP, photosensitivity was observed in 4.3% (16/372) of pa
Eintrag öffnenBraftovi · 4.8 · Renal dysfunction Melanoma and NSCLC In the Combo 450 ISP, mild, mostly Grade 1, asymptomatic blood creatinine
Eintrag öffnenBraftovi · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnen